Related Articles
What is the rationale for T-cell therapies in the treatment of smoldering MM?
During the International Myeloma Society 5th Immune Effector Cell Workshop, the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston,…
Symposium | Q&A session
The Multiple Myeloma Hub virtual symposium held on March 11, 2024 entitled “Current and future perspectives for bispecific antibodies in multiple myeloma: Le…
European Commission approves cilta-cel for the treatment of RRMM after ≥1 prior LOT
On April 22, 2024, the EC granted approval to cilta-cel for the treatment of RRMM after one or more prior therapies, including an IMiD or…
Antigen escape as a mechanism of resistance to T-cell-engaging therapies in multiple myeloma
Here, we summarize a presentation by Paola Neri on the mechanisms of antigen escape after T-cell-redirecting therapies, presented at the 5th Immune Effector Cell Therapies…
Symposium | Introduction to T-cell engagers and general mechanism of action
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the…
Symposium | BCMA-directed bispecific antibodies
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
MagnetisMM-3 trial: Patient-reported outcomes following treatment with elranatamab
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase…
Symposium | Practical management of adverse events with immunotherapies
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Lea…
Symposium | Introduction to T-cell engagers and general mechanism of action
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…